U.S. markets closed

Entheon Biomedical Corp. (ENTBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2419-0.0102 (-4.05%)
At close: 3:47PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2521
Open0.2250
BidN/A x N/A
AskN/A x N/A
Day's Range0.2250 - 0.2436
52 Week Range0.2230 - 1.5000
Volume21,738
Avg. Volume55,561
Market Cap13.072M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ENTHEON BIOMEDICAL CORP
    NSP: Lowering target price to $112.00INSPERITY INC has an Investment Rating of HOLD; a target price of $112.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Newsfile

    Leading DMT Companies to Take Stage at Molecular Masterclass: DMT Conference

    Get a free ticket to the event here: https://microdose.buzz/nwdmtToronto, Ontario--(Newsfile Corp. - September 1, 2021) - Microdose in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Small Pharma (TSXV: DMT) a neuropharmaceutical company taking a novel approach to depression drug development, Algernon Pharmaceuticals Inc. (CSE: AGN) a clinical-stage drug development company f

  • GlobeNewswire

    Microdose Psychedelic Insights Presents the Upcoming DMT Conference, a Deep Dive Into the Dynamic Field of DMT Therapeutics

    NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be hosting the upcoming DMT Conference in an entirely virtual format Sept. 9-10, 2021. The virtual event will explore the potential of DMT (“Dimethyltryptamine”) at the intersection of drug development and safety,

  • Newsfile

    Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board

    Dr. David Erritzoe to provide guidance on psychopharmacological research Vancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College's Center for Psychedelic Research, has been appointed to Entheon's Advisory B